Superior Vena Cava Stenting

Background and indications

Superior vena cava (SVC) stenting is the endovascular treatment for superior vena cava syndrome (SVCS), a medical emergency caused by SVC obstruction. Most common causes are: lung cancer (60-70%), lymphomas (10-15%), thymomas, mediastinal metastases, and central catheter/port thrombosis. SVCS presents with facial and neck edema, dyspnea, jugular distension, and thoracic collateral circulation.

Pre-procedure assessment

Assessment includes contrast-enhanced chest CT (obstruction extent, associated thrombosis), and tumor biopsy if histological diagnosis not yet established (before stenting if possible).

Procedure

Under local anesthesia and sedation, femoral venous access (most common) is obtained. Under fluoroscopic guidance, a large-caliber self-expanding stent (12-16 mm) is deployed across the SVC stenosis/occlusion. Thrombolysis or thrombectomy may precede stenting for associated acute thrombosis. The procedure takes 1 to 2 hours.

Results and scientific evidence

SVC stenting offers rapid symptom relief (within 24-72h) in 90-95% of cases. Technical success rate is 95-98%. 6-month patency is 80-90%. Recurrences are treatable by restenting. Stenting offers faster relief than radiotherapy alone for tumor-related SVCS.

Risks and complications

Access site hematoma (3-5%), stent migration (< 2%), PE (< 1%), venous perforation (< 0.5%). Stenting is considered low-risk even in severely ill patients.

Recovery

1-2 night hospitalization. Rapid symptomatic relief. Anticoagulation +/- antiplatelet. Radiation and/or chemotherapy for causative tumor in parallel.

Practical information

The procedure is performed as an inpatient (emergency context). It is performed by a vascular interventional radiologist, in coordination with the oncologist and pulmonologist.